In-House vs Outsourced PV: Strategic Trade-Offs for MAHs

The Question Behind the Operating Model

It is a question that looks tidy on a procurement slide and becomes a great deal more human the moment a serious adverse event lands in a mailbox at two in the morning. The shape of that answer — in-house, fully outsourced, or something in between — determines how quickly a patient report becomes a clinical decision, and how confidently a regulator sees the system that produced it.

We have watched our industry tilt steadily toward external partners. Contract services now account for more than 55% of pharmacovigilance activity, and the global market for outsourced safety work sits at roughly USD 7.92 billion in 2025. By any measure, outsourcing is no longer the alternative path — for most organisations, it is the default architecture of modern drug safety, and understanding the in house vs outsourced pharmacovigilance trade-offs has become essential reading for anyone responsible for a portfolio's benefit-risk profile.

The Economics That Drive the Shift

The arithmetic is, frankly, hard to argue with. Analyses of deployed pharmacovigilance operations consistently report cost savings in the 30–40% range when companies move substantial safety work to specialised vendors. That is not a marginal optimisation; it is the difference between a sustainable safety operation and one that bleeds budget from the day it launches.

But the cost story is not only about headcount. Building an in-house team means recruiting a Qualified Person for Pharmacovigilance, training medical reviewers, maintaining a validated safety database, and absorbing the fixed overhead of 24/7 availability — all before a single case has been processed. For a small or mid-cap company with a single marketed product, that fixed cost is a heavy weight on a thin margin. Outsourcing, by contrast, converts fixed cost into variable cost: you pay for the work that exists, and the vendor absorbs the spare capacity.

Outsourcing pharmacovigilance is no longer the alternative path — for most organisations, it has become the default architecture of modern drug safety.

The Dutch market illustrates the pattern clearly. The Health and Youth Care Inspectorate reported in July 2024 that 75% of Marketing Authorisation Holders outsource case processing and 82% outsource safety database maintenance. These are not experimental arrangements; they are the routine reality of how MAHs in a mature regulatory environment keep patients safe.

Operational Control vs. Scalability: Where the Hybrid Model Lives

Pure outsourcing, however, is rarely the final answer for organisations that intend to grow. As pipelines mature and portfolios expand, a different calculus emerges. Processing thousands of cases per quarter is one challenge; integrating safety data into clinical development, regulatory strategy, and signal governance is another entirely.

This is the territory where the hybrid model has earned its place. Biotech and mid-size pharma companies adopting hybrid arrangements typically retain ownership of their safety systems and the patient data that flows through them, while engaging contract research organisations to execute the high-volume processing and submission workload. The internal team becomes a strategic hub — owning the database, interpreting signals, shaping the benefit-risk narrative — while the vendor extends operational reach without requiring the company to build and rebuild capacity for every new indication.

The hybrid approach recognises something the binary framing often misses: pharmacovigilance is not a single activity but a continuum. Case intake, narrative writing, and regulatory submission can be commoditised with relative safety. Signal detection, benefit-risk interpretation, and engagement with health authorities cannot — and the moment a serious unexpected adverse reaction arrives, it is the latter set of capabilities that determines whether the response feels competent or chaotic.

The QPPV Mandate and the Question of Accountability

No discussion of operating models can sidestep the European Qualified Person for Pharmacovigilance requirement. EU regulations mandate that every Marketing Authorisation Holder have an EU-based QPPV with round-the-clock availability — and that mandate applies regardless of how the rest of the safety operation is structured. The QPPV role can be fulfilled internally or delegated to a service provider with deputy arrangements, but the obligation itself does not move with the work.

This is where the conversation turns quietly serious. Outsourcing case processing does not transfer legal accountability for drug safety from the MAH. The Marketing Authorisation Holder remains the responsible party. For companies considering full outsourcing, this distinction matters operationally: a deputy QPPV structure is often needed to ensure continuity, and the vendor relationship must be engineered to give the QPPV genuine visibility into case flow — not a curated summary arriving after the fact.

We have seen inspections where the seam between the QPPV and the vendor's processing team became uncomfortable for everyone involved. The contract may describe the relationship; the regulator will judge the evidence. And the evidence, in pharmacovigilance, is always built case by case.

The database is not a compliance artefact. It is where the lived experience of every patient who experienced an adverse event becomes a permanent clinical record.

Data Integrity and the Ownership of Safety Databases

Nowhere does the in house safety team vs CRO debate become more concrete than in the safety database itself. The Dutch Inspectorate data tells us that 82% of MAHs outsource database maintenance — a striking figure — and yet the database is where the lived experience of harm, or of near-harm, becomes a permanent clinical record that subsequent patients will rely upon without ever knowing it exists.

There is a meaningful difference between a vendor maintaining a database on your behalf and your team owning the data it contains. The former can be efficient and entirely compliant; the latter offers shorter processing cycle times, more direct query resolution, and a tighter feedback loop between the signal that emerges and the people who must act on it. When a serious adverse reaction arrives, the question is not whether the database is validated — it is how quickly your team can interrogate it, understand the context, and shape the response that follows.

EudraVigilance has collected more than 25.3 million individual case safety reports between 2001 and 2022, representing 14.8 million unique suspected adverse drug reaction cases. Each one represents a patient — and each one sits in a database somewhere, governed by someone. The mah pharmacovigilance operating model question is, at its heart, a question about who that governance serves most directly.

Strategic Decision-Making for Growing Portfolios

So how do we, as an industry, make this decision well? It is tempting to reach for the cost figure first, and for many organisations it is the right starting point. But the operating model that suits a single-asset company rarely survives a second or third launch without adjustment, and the choices that age well tend to share a few characteristics:

1. The portfolio trajectory is honoured. If the next three years will bring multiple launches across therapeutic areas, a model that scales without proportional hiring — typically hybrid — tends to age better than a fully outsourced arrangement that must be renegotiated for every new indication.

2. The nature of the safety work is matched to the model. Commoditised processing favours outsourcing; signal interpretation, regulatory engagement, and benefit-risk narrative favour internal ownership. The right answer usually lies in assigning each activity to the structure that handles it best.

3. The inspection posture the organisation wants to hold is named openly. Companies that expect to be the subject of frequent regulatory scrutiny often prefer the visibility and direct control an in-house or hybrid arrangement provides — not because outsourced partners perform poorly, but because the chain of evidence is shorter when it sits within your own walls.

The growth forecast for outsourced pharmacovigilance — a compound annual rate of roughly 15.82% through 2030 — tells us where the industry is heading in aggregate. But aggregate trends do not decide individual operating models. They only narrow the field, leaving the harder, more human choices to the teams who must live with them.

What the Bedside Reality Asks of Us

We return, as we always do in this work, to the patient. The pharmacovigilance operating model is not an organisational chart; it is the machinery through which a patient's experience of harm becomes information that protects the next patient. Whether that machinery is staffed entirely by your colleagues, entirely by a partner, or by a thoughtful blend of both, the standard is identical: timely, accurate, contextualised, and unafraid to say what the data is showing.

In our experience, the MAHs that handle this well are not the ones who chose the cheapest model or the most prestigious vendor. They are the ones who chose the model that matched their portfolio, their regulatory exposure, and their willingness to remain close to the data. The pharmacovigilance outsourcing trade-offs are real. They are also knowable — and, in this industry, that is the most reassuring thing a decision can be.

The harder work, of course, follows the decision: building the oversight, auditing the vendor, training the team, and keeping the patient's lived experience at the centre of every signal that crosses the threshold. That work does not care which operating model you chose. It only cares whether you chose it with your eyes open.